[*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed but]
[Item 4. Ownership Please see Items 5 - 9 and 11 on eachver sheet for each Reporting Person Item 5. Ownership of Five Percent or Less of a Class Not Applicable Item 6. Ownership of More than Five Percent on Behalf of Another Person Not Applicable Item 7. Identification and Classification of the Subsidiary Which]
[Item 4. Ownership Please see Items 5 - 9 and 11 on eachver sheet for each Reporting Person Item 5. Ownership of Five Percent or Less of a Class Not Applicable Item 6. Ownership of More than Five Percent on Behalf of Another Person Not Applicable Item 7. Identification and Classification of the Subsidiary Which]
[Execution Copy LOCK-UP AGREEMENT among KKR CHINA HEALTHCARE INVESTMENT LIMITED and COMPANY LIMITED Golden Meditech STEM CELL (BVI) and LIMITED Golden Meditech HOLDINGS ________________________________ Dated April 12, 2012 ________________________________ Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong TABLE OF CONTENTS Page SECTION 1 INTERPRETATION 1 SECTION]
[Execution Copy LOCK-UP AGREEMENT among KKR CHINA HEALTHCARE INVESTMENT LIMITED and COMPANY LIMITED Golden Meditech STEM CELL (BVI) and LIMITED Golden Meditech HOLDINGS ________________________________ Dated April 12, 2012 ________________________________ Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong TABLE OF CONTENTS Page SECTION 1 INTERPRETATION 1 SECTION]
[Execution Version CONVERTIBLE NOTE PURCHASE among CHINA CORD BLOOD CORPORATION and KKR CHINA HEALTHCARE INVESTMENT LIMITED Dated April 12, 2012 Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong TABLE OF CONTENTS Page Section 1 2 Section 2 9 Section 3 9 Section 4 14 Section 5] [China Cord Blood Corporation Announces Investment by KKR Hong Kong and Beijing, 12 April 2012 China Cord Blood Corporation (“CCBC”) (NYSE: CO) and Kohlberg Kravis Roberts & Co. L.P. (together with its affiliates, "KKR") announced that they have entered into agreements under which KKR China Growth Fund L.P., a China focused investment fund managed by KKR, is expected to invest]
[Executionpy LOCK-UPREEMENT amongR CHINA HEALTHCARE INVESTMENT LIMITED andMPANY LIMITED Golden Meditech STEM CELL (BVI) and LIMITED Golden MeditechS ________________________________ted April 12, 2012 ________________________________ Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong]
[Executionpy LOCK-UPREEMENT amongR CHINA HEALTHCARE INVESTMENT LIMITED andMPANY LIMITED Golden Meditech STEM CELL (BVI) and LIMITED Golden MeditechS ________________________________ted April 12, 2012 ________________________________ Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong]
[Execution VersionNVERTIBLE NOTE PURCHASE among CHINARD BLOODRPORATION andR CHINA HEALTHCARE INVESTMENT LIMITEDted April 12, 2012 Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong TABLE OFNTENTS Page Section 1 2 Section 2] [Chinard Bloodrporation Announces Investment byR Hong Kong and Beijing, 12 April 2012 Chinard Bloodrporation (CCBC) (NYSE:) and Kohlberg Kravis Roberts & L.P. (together with its affiliates, "KKR") announced that they have entered intoreements under whichR China Growth Fund L.P., a China focused investment fund managed byR, is expected to invest $65 million into CCBC, the]
[China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012 3Q12 Revenue Up 4.8% YOY to RMB94.8 Million 3Q12 Net Income Attributable to Shareholders Up 52.5% to RMB39.5 Million Conference Call to be Held February 28, 2012 at 8:00 am ET HONG KONG, China, February 27, 2012 — China Cord Blood Corporation]
